Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States.
CBTRUS
IDH
biomarkers
brain tumor
molecular epidemiology
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
02 11 2022
02 11 2022
Historique:
pubmed:
24
4
2022
medline:
4
11
2022
entrez:
23
4
2022
Statut:
ppublish
Résumé
Selected molecular biomarkers were incorporated into the US cancer registry reporting for patients with brain tumors beginning in 2018. We investigated the completeness and validity of these variables and described the epidemiology of molecularly defined brain tumor types. Brain tumor patients with histopathologically confirmed diagnosis in 2018 were identified within the Central Brain Tumor Registry of the United States and NCI's Surveillance, Epidemiology, and End Results Incidence databases. The brain molecular markers (BMM) site-specific data item was assessed for coding completeness and validity. 1p/19q status, MGMT promoter methylation, WHO grade data items, and new ICD-O-3 codes were additionally evaluated. These data were used to profile the characteristics and age-adjusted incidence rates per 100 000 population of molecularly defined brain tumors with 95% confidence intervals (95% CI). BMM completeness across the applicable tumor types was 75%-92% and demonstrated favorable coding validity. IDH-wildtype glioblastomas' incidence rate was 1.74 (95% CI: 1.69-1.78), as compared to 0.14 for WHO grade 2 (95% CI: 0.12-0.15), 0.15 for grade 3 (95% CI: 0.14-0.16), and 0.07 for grade 4 (95% CI: 0.06-0.08) IDH-mutant astrocytomas. Irrespective of WHO grade, IDH mutation prevalence was highest in adolescent and young adult patients, and IDH-mutant astrocytomas were more frequently MGMT promoter methylated. Among pediatric-type tumors, the incidence rate was 0.06 for H3K27M-mutant diffuse midline gliomas (95% CI: 0.05-0.07), 0.03 for SHH-activated/TP53-wildtype medulloblastomas (95% CI: 0.02-0.03), and <0.01 for both C19MC-altered embryonal tumor with multilayered rosettes and RELA-fusion ependymomas. Our findings illustrate the success of developing a dedicated, integrated diagnosis variable, which provides critical molecular information about brain tumors related to accurate diagnosis.
Sections du résumé
BACKGROUND
Selected molecular biomarkers were incorporated into the US cancer registry reporting for patients with brain tumors beginning in 2018. We investigated the completeness and validity of these variables and described the epidemiology of molecularly defined brain tumor types.
METHODS
Brain tumor patients with histopathologically confirmed diagnosis in 2018 were identified within the Central Brain Tumor Registry of the United States and NCI's Surveillance, Epidemiology, and End Results Incidence databases. The brain molecular markers (BMM) site-specific data item was assessed for coding completeness and validity. 1p/19q status, MGMT promoter methylation, WHO grade data items, and new ICD-O-3 codes were additionally evaluated. These data were used to profile the characteristics and age-adjusted incidence rates per 100 000 population of molecularly defined brain tumors with 95% confidence intervals (95% CI).
RESULTS
BMM completeness across the applicable tumor types was 75%-92% and demonstrated favorable coding validity. IDH-wildtype glioblastomas' incidence rate was 1.74 (95% CI: 1.69-1.78), as compared to 0.14 for WHO grade 2 (95% CI: 0.12-0.15), 0.15 for grade 3 (95% CI: 0.14-0.16), and 0.07 for grade 4 (95% CI: 0.06-0.08) IDH-mutant astrocytomas. Irrespective of WHO grade, IDH mutation prevalence was highest in adolescent and young adult patients, and IDH-mutant astrocytomas were more frequently MGMT promoter methylated. Among pediatric-type tumors, the incidence rate was 0.06 for H3K27M-mutant diffuse midline gliomas (95% CI: 0.05-0.07), 0.03 for SHH-activated/TP53-wildtype medulloblastomas (95% CI: 0.02-0.03), and <0.01 for both C19MC-altered embryonal tumor with multilayered rosettes and RELA-fusion ependymomas.
CONCLUSIONS
Our findings illustrate the success of developing a dedicated, integrated diagnosis variable, which provides critical molecular information about brain tumors related to accurate diagnosis.
Identifiants
pubmed: 35460555
pii: 6573306
doi: 10.1093/neuonc/noac113
pmc: PMC9629432
doi:
Substances chimiques
Biomarkers
0
Isocitrate Dehydrogenase
EC 1.1.1.41
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, P.H.S.
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1989-2000Subventions
Organisme : NCI NIH HHS
ID : K12 CA090354
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA014051
Pays : United States
Commentaires et corrections
Type : ErratumIn
Informations de copyright
Published by Oxford University Press on behalf of the Society for Neuro-Oncology 2022.
Références
JAMA Oncol. 2020 Dec 1;6(12):1972-1974
pubmed: 33090181
Am J Clin Oncol. 2017 Oct;40(5):498-506
pubmed: 25844824
J Clin Oncol. 2013 Jan 20;31(3):337-43
pubmed: 23071247
J Clin Oncol. 2013 Aug 10;31(23):2927-35
pubmed: 23835706
Neurooncol Pract. 2019 Sep;6(5):330-339
pubmed: 31555447
J Natl Compr Canc Netw. 2017 Nov;15(11):1331-1345
pubmed: 29118226
Acta Neuropathol. 2012 Apr;123(4):473-84
pubmed: 22358457
Neuro Oncol. 2019 Dec 17;21(12):1498-1508
pubmed: 31276167
J Neurooncol. 2015 May;123(1):43-51
pubmed: 25864099
Acta Neuropathol. 2020 Mar;139(3):603-608
pubmed: 31996992
Brain Pathol. 2020 Sep;30(5):863-866
pubmed: 32502305
Cancer Res. 2006 Oct 15;66(20):9852-61
pubmed: 17047046
Acta Neuropathol. 2018 Mar;135(3):481-484
pubmed: 29372318
Lancet Oncol. 2012 Sep;13(9):916-26
pubmed: 22877848
N Engl J Med. 2005 Mar 10;352(10):997-1003
pubmed: 15758010
Nature. 2017 Jul 19;547(7663):311-317
pubmed: 28726821
N Engl J Med. 2015 Jun 25;372(26):2499-508
pubmed: 26061753
Brain Pathol. 2020 Jul;30(4):844-856
pubmed: 32307792
Cancer Cell. 2015 May 11;27(5):728-43
pubmed: 25965575
Lancet Oncol. 2012 Jul;13(7):707-15
pubmed: 22578793
Nat Rev Cancer. 2020 Jan;20(1):42-56
pubmed: 31819232
Acta Neuropathol. 2018 Nov;136(5):805-810
pubmed: 30259105
Acta Neuropathol. 2010 Dec;120(6):707-18
pubmed: 21088844
J Neurooncol. 2016 Oct;130(1):31-42
pubmed: 27418206
Neuro Oncol. 2018 Feb 19;20(3):295-298
pubmed: 29471448
Acta Neuropathol. 2018 Apr;135(4):639-642
pubmed: 29497819
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
Clin Cancer Res. 2019 Apr 15;25(8):2656-2663
pubmed: 30635340
Acta Neuropathol. 2019 Apr;137(4):683-687
pubmed: 30848347
N Engl J Med. 2009 Feb 19;360(8):765-73
pubmed: 19228619
Stat Methods Med Res. 2006 Dec;15(6):547-69
pubmed: 17260923
J Clin Oncol. 2013 Jan 20;31(3):344-50
pubmed: 23071237
Neuro Oncol. 2021 Oct 5;23(12 Suppl 2):iii1-iii105
pubmed: 34608945